Home > Publications Database > Intravenous thrombolysis before percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome and acute ischaemic stroke: a subanalysis of the PRAISE study. > print

001     281516
005     20251030102703.0
024 7 _ |a 10.1136/openhrt-2025-003567
|2 doi
024 7 _ |a pmid:41022535
|2 pmid
024 7 _ |a 2398-595X
|2 ISSN
024 7 _ |a 2053-3624
|2 ISSN
037 _ _ |a DZNE-2025-01135
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sedghi, Annahita
|b 0
245 _ _ |a Intravenous thrombolysis before percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome and acute ischaemic stroke: a subanalysis of the PRAISE study.
260 _ _ |a London
|c 2025
|b BMJ
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1761732322_30627
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a In patients with acute ischaemic stroke (AIS) and concomitant non-ST-elevation acute coronary syndrome (NSTE-ACS), the role of intravenous thrombolysis (IVT) before percutaneous coronary intervention (PCI) is unclear.We performed a subanalysis of the PRAISE (PRediction of Acute coronary syndrome in acute Ischemic StrokE) study, a multicentre, prospective observational study in 247 patients with AIS and elevated high-sensitivity cardiac troponin who underwent coronary angiography based on European Society of Cardiology guidelines. The impact of IVT prior to PCI on coronary artery flow (Thrombolysis in Myocardial Infarction (TIMI) score) and myocardial perfusion (TIMI myocardial perfusion score) was compared using Fisher's exact test and logistic regression analysis, adjusting for time from stroke onset to PCI.Among 71 patients with AIS undergoing PCI, those who received IVT prior to PCI for NSTE-ACS (33 women; median age 77 (66-82 IQR)) achieved a TIMI grade 3 flow more frequently than those undergoing direct PCI (97% vs 79%; p=0.04). Regression analysis indicated a trend toward improved coronary artery flow with IVT (adjusted OR 8.5, 95% CI 0.9 to 75.3; p=0.05). Myocardial perfusion did not differ between groups (p=0.06).This subanalysis suggests that IVT before PCI may enhance coronary artery flow in selected patients with NSTE-ACS with AIS. The results of this exploratory subanalysis warrant further investigation, particularly in patients with delayed access to PCI.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Acute Coronary Syndrome
|2 Other
650 _ 7 |a Atherosclerosis
|2 Other
650 _ 7 |a Percutaneous Coronary Intervention
|2 Other
650 _ 7 |a Pharmacology, Clinical
|2 Other
650 _ 7 |a Stroke
|2 Other
650 _ 7 |a Fibrinolytic Agents
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Percutaneous Coronary Intervention: adverse effects
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Acute Coronary Syndrome: therapy
|2 MeSH
650 _ 2 |a Acute Coronary Syndrome: complications
|2 MeSH
650 _ 2 |a Acute Coronary Syndrome: diagnosis
|2 MeSH
650 _ 2 |a Acute Coronary Syndrome: physiopathology
|2 MeSH
650 _ 2 |a Thrombolytic Therapy: methods
|2 MeSH
650 _ 2 |a Thrombolytic Therapy: adverse effects
|2 MeSH
650 _ 2 |a Ischemic Stroke: complications
|2 MeSH
650 _ 2 |a Ischemic Stroke: drug therapy
|2 MeSH
650 _ 2 |a Ischemic Stroke: diagnosis
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Fibrinolytic Agents: administration & dosage
|2 MeSH
650 _ 2 |a Fibrinolytic Agents: adverse effects
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
650 _ 2 |a Coronary Angiography
|2 MeSH
650 _ 2 |a Administration, Intravenous
|2 MeSH
650 _ 2 |a Coronary Circulation
|2 MeSH
650 _ 2 |a Time Factors
|2 MeSH
700 1 _ |a von Rennenberg, Regina
|0 P:(DE-2719)9001452
|b 1
|u dzne
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 2
|u dzne
700 1 _ |a Nickenig, Georg
|b 3
700 1 _ |a Kallmünzer, Bernd
|b 4
700 1 _ |a Achenbach, Stephan
|b 5
700 1 _ |a Huber, Roman
|b 6
700 1 _ |a Seeger, Julia
|b 7
700 1 _ |a von Sarnowski, Bettina
|b 8
700 1 _ |a Thomalla, Goetz
|b 9
700 1 _ |a Ringleb, Peter Arthur
|b 10
700 1 _ |a Michalski, Dominik
|b 11
700 1 _ |a Laufs, Ulrich
|b 12
700 1 _ |a Royl, Georg
|b 13
700 1 _ |a Szabo, Kristina
|b 14
700 1 _ |a Mangner, Norman
|b 15
700 1 _ |a Puetz, Volker
|b 16
700 1 _ |a Kellert, Lars
|0 P:(DE-2719)9003034
|b 17
|u dzne
700 1 _ |a Kaeaeb, Stefan
|b 18
700 1 _ |a Wunderlich, Silke
|b 19
700 1 _ |a Laugwitz, Karl-Ludwig
|b 20
700 1 _ |a Petersen, Martina
|b 21
700 1 _ |a Mengel, Annerose
|0 P:(DE-2719)9003061
|b 22
|u dzne
700 1 _ |a Leistner, David M
|b 23
700 1 _ |a Landmesser, Ulf
|b 24
700 1 _ |a Endres, Matthias
|0 P:(DE-2719)2811033
|b 25
|u dzne
700 1 _ |a Nolte, Christian H
|b 26
700 1 _ |a Siepmann, Timo
|0 0000-0003-2196-5904
|b 27
773 _ _ |a 10.1136/openhrt-2025-003567
|g Vol. 12, no. 2, p. e003567 -
|0 PERI:(DE-600)2747269-3
|n 2
|p e003567
|t Open Heart
|v 12
|y 2025
|x 2398-595X
856 4 _ |u https://pub.dzne.de/record/281516/files/DZNE-2025-01135%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281516/files/DZNE-2025-01135.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/281516/files/DZNE-2025-01135%20SUP.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281516/files/DZNE-2025-01135.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281516
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-2719)9001452
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)2810273
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 17
|6 P:(DE-2719)9003034
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)9003061
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2811033
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-24T13:17:53Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-24T13:17:53Z
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-01-24T13:17:53Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1811005
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21